Does Lexapro Have Anticholinergic Activity?
Lexapro (escitalopram) has minimal to no clinically significant anticholinergic activity at therapeutic doses.
Evidence from Drug Label and Pharmacology
The FDA drug label for escitalopram explicitly states that it "has no or very low affinity for...muscarinic (M1-5) receptors" 1. This is the mechanism by which anticholinergic side effects occur—through muscarinic receptor blockade—and escitalopram simply does not bind to these receptors in any meaningful way 1.
The drug label further clarifies that "antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular side effects of other psychotropic drugs," but escitalopram lacks this property 1. Even the metabolites of escitalopram (S-DCT and S-DDCT) "have no or very low affinity for...muscarinic (M1-5) receptors" 1.
Comparative Evidence from Research Studies
A rigorous radioreceptor assay study measuring anticholinergic activity of 107 medications commonly used by older adults found that escitalopram demonstrated anticholinergic activity of less than 5 pmol/mL of atropine equivalents—placing it in the lowest category of measurable activity 2. For context, medications with strong anticholinergic effects (like amitriptyline, atropine, and oxybutynin) showed values exceeding 15 pmol/mL, while paroxetine (another SSRI) showed moderate activity of 5-15 pmol/mL 2.
Citalopram, the racemic mixture from which escitalopram is derived, was similarly found to have "minimal anticholinergic effects" in clinical trials 3. Multiple pharmacokinetic reviews confirm that escitalopram has "negligible inhibitory effects" on receptors associated with anticholinergic side effects 4, 5.
Clinical Implications in Older Adults
This lack of anticholinergic activity is precisely why escitalopram is recommended as a preferred antidepressant in older adults 6. The 2015 American Family Physician guidelines explicitly list escitalopram among preferred agents with "favorable adverse effect profiles" and note that it has "no" anticholinergic effects, in contrast to paroxetine which "is associated with more anticholinergic effects" and should not be used in older adults 6.
The 2021 Mayo Clinic Proceedings guidelines on polypharmacy management emphasize that "strongly anticholinergic medications" like diphenhydramine, cyclobenzaprine, and oxybutynin should be deprescribed in older adults due to their "broad muscarinic receptor blockade" causing negative effects on "vision, urination, constipation, and cognition" 6. Escitalopram is not included in this category of concern.
Practical Clinical Context
When managing depression in elderly patients or those with dementia, escitalopram is specifically chosen because it lacks anticholinergic burden 6. The 2002 American Family Physician guidelines on Alzheimer's disease management state that "the most useful medications are those with minimal anticholinergic side effects" and specifically recommend "selective serotonin reuptake inhibitors, such as citalopram (Celexa) and sertraline (Zoloft)" as "agents of choice" 6.
Common Pitfall to Avoid
Do not confuse escitalopram with paroxetine—while both are SSRIs, paroxetine has measurable anticholinergic activity (5-15 pmol/mL) and is explicitly contraindicated in older adults due to this property 6, 2. Escitalopram's anticholinergic activity is essentially negligible (<5 pmol/mL) and poses no clinically relevant anticholinergic burden 2, 5.